PMID- 35745791
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 14
IP  - 6
DP  - 2022 Jun 8
TI  - Associations of GNAS and RGS Gene Polymorphisms with the Risk of 
      Ritodrine-Induced Adverse Events in Korean Women with Preterm Labor: A Cohort 
      Study.
LID - 10.3390/pharmaceutics14061220 [doi]
LID - 1220
AB  - Ritodrine, a beta2-adrenergic receptor agonist, is among most commonly prescribed 
      tocolytic agents. This study aimed to evaluate the associations of single 
      nucleotide polymorphisms in GNAS, RGS2, and RGS5 with the risk of 
      ritodrine-induced adverse events (AEs) and develop a risk scoring system to 
      identify high-risk patients. This is the prospective cohort study conducted at 
      the Ewha Woman's University Mokdong Hospital between January 2010 and October 
      2016. Pregnant women were included if they were treated with ritodrine for 
      preterm labor with regular uterine contractions (at least 3 every 10 min) and 
      cervical dilation. A total of 6, 3, and 5 single nucleotide polymorphisms (SNPs) 
      of GNAS, RGS2, and RGS5 genes were genotyped and compared in patients with and 
      without ritodrine-induced AEs. A total of 163 patients were included in this 
      study. After adjusting confounders, GNAS rs3730168 (per-allele odds ratio (OR): 
      2.1; 95% confidence interval (95% CI): 1.0-4.3) and RGS2 rs1152746 (per-allele 
      OR: 2.6, 95% CI: 1.1-6.5) were significantly associated with ritodrine-induced 
      AEs. According to the constructed risk scoring models, patients with 0, 1, 2, 3, 
      4, and 5 points showed 0%, 13%, 19%, 31%, 46%, and 100% risks of AEs. This study 
      suggested that GNAS and RGS2 polymorphisms could affect the risk of AEs in 
      patients treated with ritodrine.
FAU - Jang, Eun-Jeong
AU  - Jang EJ
AD  - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans 
      University, Seoul 03760, Korea.
FAU - Kim, Young-Ju
AU  - Kim YJ
AUID- ORCID: 0000-0002-3153-3008
AD  - Department of Obstetrics and Gynecology, Ewha Womans University School of 
      Medicine, Seoul 07985, Korea.
FAU - Hwang, Han-Sung
AU  - Hwang HS
AUID- ORCID: 0000-0003-0622-0701
AD  - Department of Obstetrics and Gynecology, Konkuk University Medical Center, Konkuk 
      University School of Medicine, Seoul 05030, Korea.
FAU - Yee, Jeong
AU  - Yee J
AD  - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans 
      University, Seoul 03760, Korea.
FAU - Gwak, Hye-Sun
AU  - Gwak HS
AUID- ORCID: 0000-0003-0278-2563
AD  - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans 
      University, Seoul 03760, Korea.
LA  - eng
GR  - NRF-2010-0022544/National Research Foundation of Korea/
GR  - HI14C0306/Korea Health Industry Development Institute/Republic of Korea
PT  - Journal Article
DEP - 20220608
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC9227008
OTO - NOTNLM
OT  - GNAS
OT  - RGS2
OT  - RGS5
OT  - adverse events
OT  - polymorphisms
OT  - ritodrine
COIS- The authors declare no conflict of interest.
EDAT- 2022/06/25 06:00
MHDA- 2022/06/25 06:01
PMCR- 2022/06/08
CRDT- 2022/06/24 01:38
PHST- 2022/05/06 00:00 [received]
PHST- 2022/06/02 00:00 [revised]
PHST- 2022/06/07 00:00 [accepted]
PHST- 2022/06/24 01:38 [entrez]
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/06/25 06:01 [medline]
PHST- 2022/06/08 00:00 [pmc-release]
AID - pharmaceutics14061220 [pii]
AID - pharmaceutics-14-01220 [pii]
AID - 10.3390/pharmaceutics14061220 [doi]
PST - epublish
SO  - Pharmaceutics. 2022 Jun 8;14(6):1220. doi: 10.3390/pharmaceutics14061220.